Exact Sciences Corp
Exact Sciences Announces First-Quarter 2024 Financial Results
Summary
Exact Sciences Corp. announced its financial results for the first quarter of 2024, reporting total revenue of $638 million, a 6% increase from the same period in 2023. The company maintained its full-year 2024 revenue and adjusted EBITDA guidance. Screening revenue increased by 7% to $475 million, and Precision Oncology revenue increased by 5% to $163 million. The company will host a conference call on May 8, 2024, to discuss these results.
Profitelligence Alerts
Get alerts for EXAS
Be first to know when Exact Sciences Corp files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About Exact Sciences Corp
Exact Sciences Corp is a prominent biomedical and biotechnology company dedicated to the development, manufacturing, and marketing of proprietary diagnostic tests. Headquartered in Madison, Wisconsin, the company is renowned for its innovative work in the early detection and prevention of colorectal cancer, primarily through its flagship product, Cologuard. This non-invasive stool-based DNA screening test is a breakthrough in cancer diagnostics, allowing for easier and earlier detection of cancerous and pre-cancerous conditions without the need for traditional invasive procedures. Exact Sciences plays a vital role in the health care and life sciences sectors, significantly impacting patient care by providing more accessible screening options. Their commitment to research and development is evident through ongoing efforts to expand their diagnostic offerings, which include tests for other critical health conditions. In the financial markets, Exact Sciences is a key player in the medical diagnostics and biotechnology industries, with substantial influence on the development of new cancer screening methodologies. The company's innovative approach not only aims to improve patient outcomes but also helps reduce costs in healthcare by enabling timely interventions.
Official SEC Documents
Advertisement